Oh-Seung Kwon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Oh-Seung Kwon has a total of 257 co-authors. Here are the top co-authors by number of shared publications:
- Mahbub Hasan
Department of Digital Healthcare Engineering, College of Health Sciences, Sangji University 1 , Wonju 26339, South Korea
12 shared publications Ho Jun Kim
11 shared publicationsJi-Eun Seo
Doping Control Center, Korea Institute of Science and Technology, Seoul, Republic of Korea
11 shared publications- Jaeick Lee
Doping Control Center, KIST, Seoul 02792, Republic of Korea
10 shared publications Kang Mi Lee
10 shared publicationsMin-Jung Kang
Division of Bio-Medical Science & Technology, KIST School, University of Science and Technology, Seoul 02792, Republic of Korea; Center for Advanced Biomolecular Recognition, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea
10 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 30
Functional Characterization of N -acetyl- l -Leucyl- l -Lysine Supports a Peptide Prodrug Mechanism for TB-500
The therapeutic application of peptides has expanded considerably in clinical and regenerative medicine; however, the contribution of peptide metabolites to therapeutic efficacy remains poorly understood. We previously identified N -acetyl- l -leucyl- l -lysine (Ac-LK) as the major metabolite of TB-500 by metabolic profiling and hypothesized that it contributes to the biological activity of the parent peptide. Initial screening demonstrated that Ac-LK exhibited greater SARS-CoV-2 main protease inhibitory activity than TB-500, the other identified metabolites, and the constituent amino acids. We therefore systematically characterized Ac-LK using cellular uptake, endothelial cell functional assays, proteomic profiling, and in vivo wound healing. Under the experimental conditions employed, Ac-LK exhibited enhanced protection against hypoxia/reoxygenation-induced injury, stronger promigratory and barrier-stabilizing activities, broader regulation of pathways related to cytoskeletal organization, cadherin-mediated adhesion, and protein translation, and accelerated wound healing. Collectively, these findings identify Ac-LK as a biologically active metabolite of TB-500 and support the hypothesis that metabolic conversion contributes to the therapeutic actions of the parent peptide.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 30
Open AccessFunctional Characterization of N -acetyl- l -Leucyl- l -Lysine Supports a Peptide Prodrug Mechanism for TB-500
The therapeutic application of peptides has expanded considerably in clinical and regenerative medicine; however, the contribution of peptide metabolites to therapeutic efficacy remains poorly understood. We previously identified N -acetyl- l -leucyl- l -lysine (Ac-LK) as the major metabolite of TB-500 by metabolic profiling and hypothesized that it contributes to the biological activity of the parent peptide. Initial screening demonstrated that Ac-LK exhibited greater SARS-CoV-2 main protease inhibitory activity than TB-500, the other identified metabolites, and the constituent amino acids. We therefore systematically characterized Ac-LK using cellular uptake, endothelial cell functional assays, proteomic profiling, and in vivo wound healing. Under the experimental conditions employed, Ac-LK exhibited enhanced protection against hypoxia/reoxygenation-induced injury, stronger promigratory and barrier-stabilizing activities, broader regulation of pathways related to cytoskeletal organization, cadherin-mediated adhesion, and protein translation, and accelerated wound healing. Collectively, these findings identify Ac-LK as a biologically active metabolite of TB-500 and support the hypothesis that metabolic conversion contributes to the therapeutic actions of the parent peptide.
- Open Access
- 1 July 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 49, 437-455
Protein to biomaterials: Unraveling the antiviral and proangiogenic activities of Ac-Tβ1-17 peptide, a thymosin β4 metabolite, and its implications in peptide-scaffold preparation
Peptide metabolites are emerging biomolecules with numerous possibilities in biomaterial-based regenerative medicine due to their inherent bioactivities. These small, naturally occurring compounds are intermediates or byproducts of larger proteins and peptides, and they can have profound effects, such as antiviral therapeutics, proangiogenic agents, and regenerative medicinal applications. This study is among the first to focus on using thymosin β4 protein-derived metabolites to pioneer novel applications for peptide metabolites in biomaterials. This study found that the novel peptide metabolite acetyl-thymosin β4 (amino acid 1–17) (Ac-Tβ1-17) exhibited significant protease inhibition activity against SARS-CoV-2, surpassing its precursor protein. Additionally, Ac-Tβ1-17 demonstrated beneficial effects, such as cell proliferation, wound healing, and scavenging of reactive oxygen species (ROS) in human umbilical vein endothelial cells (HUVEC). Integrating Ac-Tβ1-17 into a peptide-based scaffold facilitated cell growth and angiogenesis inside the scaffold and through gradual release into the surrounding environment. The Ac-Tβ1-17 peptide treatment induced significant biochemical responses in HUVEC, increasing Akt, ERK, PI3K, MEK, and Bcl-2 gene expression and proangiogenic proteins. Ac-Tβ1-17 peptide treatment showed similar results in ex vivo by enhancing mouse fetal metatarsal growth and angiogenesis. These findings highlight the potential of natural protein metabolites to generate biologically active peptides, offering a novel strategy for enhancing biomaterial compatibility. This approach holds promise for developing therapeutic biomaterials using peptide metabolites, presenting exciting prospects for future research and applications.
- 1 July 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 49, 437-455
Open AccessProtein to biomaterials: Unraveling the antiviral and proangiogenic activities of Ac-Tβ1-17 peptide, a thymosin β4 metabolite, and its implications in peptide-scaffold preparation
Peptide metabolites are emerging biomolecules with numerous possibilities in biomaterial-based regenerative medicine due to their inherent bioactivities. These small, naturally occurring compounds are intermediates or byproducts of larger proteins and peptides, and they can have profound effects, such as antiviral therapeutics, proangiogenic agents, and regenerative medicinal applications. This study is among the first to focus on using thymosin β4 protein-derived metabolites to pioneer novel applications for peptide metabolites in biomaterials. This study found that the novel peptide metabolite acetyl-thymosin β4 (amino acid 1–17) (Ac-Tβ1-17) exhibited significant protease inhibition activity against SARS-CoV-2, surpassing its precursor protein. Additionally, Ac-Tβ1-17 demonstrated beneficial effects, such as cell proliferation, wound healing, and scavenging of reactive oxygen species (ROS) in human umbilical vein endothelial cells (HUVEC). Integrating Ac-Tβ1-17 into a peptide-based scaffold facilitated cell growth and angiogenesis inside the scaffold and through gradual release into the surrounding environment. The Ac-Tβ1-17 peptide treatment induced significant biochemical responses in HUVEC, increasing Akt, ERK, PI3K, MEK, and Bcl-2 gene expression and proangiogenic proteins. Ac-Tβ1-17 peptide treatment showed similar results in ex vivo by enhancing mouse fetal metatarsal growth and angiogenesis. These findings highlight the potential of natural protein metabolites to generate biologically active peptides, offering a novel strategy for enhancing biomaterial compatibility. This approach holds promise for developing therapeutic biomaterials using peptide metabolites, presenting exciting prospects for future research and applications.
- Open Access
- 19 May 2025
- Published by Wiley in Drug Testing and Analysis
- Vol. 17 (10) , 1985-1995
Metabolic Identification Based on Proposed Mass Fragmentation Pathways of the Anabolic Steroid Bolasterone by Gas Chromatography Tandem Mass Spectrometry
Bolasterone (7α,17α‐dimethyl‐androsta‐4‐en‐17β‐ol‐3‐one) was registered on the World Anti‐Doping Agency's Prohibited list of substances. This study was aimed at evaluating the metabolism of bolasterone through in vitro (liver microsomes) and in vivo (rat urine) experiments to propose mass fragmentation pathways of the metabolites by gas chromatography–quadrupole tandem mass spectrometry (GC‐EI‐MS/MS). Their plausible chemical structures were suggested based on their fragmentation pathways to overcome the lack of available authentic standards. A total of 12 metabolites (5 mono‐hydroxylated M1 to M5 and 7 di‐hydroxylated M6 to M12) after trimethylsilylation were observed. Key diagnostic ions included m/z 403 (mono‐hydroxylated) and m/z 491 (di‐hydroxylated) with m/z 143, indicating an intact D ring (M1 to M5, M7, M9, M10, M11). Hydroxylation at the D ring (M6, M12) was characterized by ions m/z 231 or 219. Hydroxylation at the A (M5, M7) or B (M2/M3, M10) rings corresponded to m/z 281 and hydroxylation at C12 of the C ring (M4, M10) was indicated by m/z 285. Based on the comparison with bolasterone analogues such as testosterone and methyltestosterone and the interpretation of fragmentation pathways, the mono‐hydroxylation metabolites M1 (at C11), M2 / M3 (at C6), M4 (at C12), M5 (at C2), and di‐hydroxylation metabolites M6 (at C11 and C16), M7 (at C2 and C11), M10 (at C6 and C12), and M12 (at C12 and C16) were proposed. The hydroxylation sites of M8 , M9 , and M11 could not be determined. This data can be useful for identifying hydroxylated metabolites by interpreting mass spectra of anabolic steroids with no standards available.
- 19 May 2025
- Published by Wiley in Drug Testing and Analysis
- Vol. 17 (10) , 1985-1995
Open AccessMetabolic Identification Based on Proposed Mass Fragmentation Pathways of the Anabolic Steroid Bolasterone by Gas Chromatography Tandem Mass Spectrometry
Bolasterone (7α,17α‐dimethyl‐androsta‐4‐en‐17β‐ol‐3‐one) was registered on the World Anti‐Doping Agency's Prohibited list of substances. This study was aimed at evaluating the metabolism of bolasterone through in vitro (liver microsomes) and in vivo (rat urine) experiments to propose mass fragmentation pathways of the metabolites by gas chromatography–quadrupole tandem mass spectrometry (GC‐EI‐MS/MS). Their plausible chemical structures were suggested based on their fragmentation pathways to overcome the lack of available authentic standards. A total of 12 metabolites (5 mono‐hydroxylated M1 to M5 and 7 di‐hydroxylated M6 to M12) after trimethylsilylation were observed. Key diagnostic ions included m/z 403 (mono‐hydroxylated) and m/z 491 (di‐hydroxylated) with m/z 143, indicating an intact D ring (M1 to M5, M7, M9, M10, M11). Hydroxylation at the D ring (M6, M12) was characterized by ions m/z 231 or 219. Hydroxylation at the A (M5, M7) or B (M2/M3, M10) rings corresponded to m/z 281 and hydroxylation at C12 of the C ring (M4, M10) was indicated by m/z 285. Based on the comparison with bolasterone analogues such as testosterone and methyltestosterone and the interpretation of fragmentation pathways, the mono‐hydroxylation metabolites M1 (at C11), M2 / M3 (at C6), M4 (at C12), M5 (at C2), and di‐hydroxylation metabolites M6 (at C11 and C16), M7 (at C2 and C11), M10 (at C6 and C12), and M12 (at C12 and C16) were proposed. The hydroxylation sites of M8 , M9 , and M11 could not be determined. This data can be useful for identifying hydroxylated metabolites by interpreting mass spectra of anabolic steroids with no standards available.
- Open Access
- 6 February 2024
- Published by Elsevier in Journal of Chromatography B
- Vol. 1235, 124033
Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro
- 6 February 2024
- Published by Elsevier in Journal of Chromatography B
- Vol. 1235, 124033
Open AccessSimultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro
- Open Access
- 28 July 2023
- Published by Wiley in Drug Testing and Analysis
- Vol. 15 (11-12) , 1454-1467
Detection and quantification of the metabolite Ac‐Tβ1–14 in in vitro experiments and urine of rats treated with Ac‐Tβ4: A potential biomarker of Ac‐Tβ4 for doping tests
Thymosin β4 (Tβ4) was reported to exert various beneficial bioactivities such as tissue repair, anti‐inflammation, and reduced scar formation, and it is listed on the prohibited substances in sports by the World Anti‐Doping Agency. However, no metabolism studies of Tβ4 were reported yet. Previously, our lab reported in in vitro experiment that a total of 13 metabolites were found by using multiple enzymes, and six metabolites (Ac‐Tβ31–43, Ac‐Tβ17–43, Ac‐Tβ1–11, Ac‐Tβ1–14, Ac‐Tβ1–15, and Ac‐Tβ1–17) were confirmed by comparing with the synthetic standards. This study was aimed at identifying new metabolites of Tβ4 leucine aminopeptidase (LAP), human kidney microsomes (HKM), cultured huvec cells, and rats after administration of Tβ4 protein to develop biomarkers for detecting doping drugs in sports. A method for detecting and quantifying Ac‐Tβ1–14 was developed and validated using Q‐Exactive orbitrap mass spectrometry. The limit of detection (LOD) and limit of quantification (LOQ) of the Ac‐Tβ1–14 were 0.19 and 0.58 ng/mL, respectively, and showed a good linearity (r2 = 0.9998). As a result, among the six metabolites above, Ac‐Tβ1–14, as a common metabolite, was found in LAP, HKM, huvec cells exposed to Tβ4, and the urine of rats intraperitoneally treated with 20‐mg/kg Tβ4. And the metabolite Ac‐Tβ1–14 was quantitatively determined by 48 h in rats, with the highest concentration occurring between 0 and 6 h. Ac‐Tβ1–14 was not detected in non‐treated control groups, including human blank urine. These results suggest that Ac‐Tβ1–14 in urine is a potential biomarker for screening the parent Tβ4 in doping tests.
- 28 July 2023
- Published by Wiley in Drug Testing and Analysis
- Vol. 15 (11-12) , 1454-1467
Open AccessDetection and quantification of the metabolite Ac‐Tβ1–14 in in vitro experiments and urine of rats treated with Ac‐Tβ4: A potential biomarker of Ac‐Tβ4 for doping tests
Thymosin β4 (Tβ4) was reported to exert various beneficial bioactivities such as tissue repair, anti‐inflammation, and reduced scar formation, and it is listed on the prohibited substances in sports by the World Anti‐Doping Agency. However, no metabolism studies of Tβ4 were reported yet. Previously, our lab reported in in vitro experiment that a total of 13 metabolites were found by using multiple enzymes, and six metabolites (Ac‐Tβ31–43, Ac‐Tβ17–43, Ac‐Tβ1–11, Ac‐Tβ1–14, Ac‐Tβ1–15, and Ac‐Tβ1–17) were confirmed by comparing with the synthetic standards. This study was aimed at identifying new metabolites of Tβ4 leucine aminopeptidase (LAP), human kidney microsomes (HKM), cultured huvec cells, and rats after administration of Tβ4 protein to develop biomarkers for detecting doping drugs in sports. A method for detecting and quantifying Ac‐Tβ1–14 was developed and validated using Q‐Exactive orbitrap mass spectrometry. The limit of detection (LOD) and limit of quantification (LOQ) of the Ac‐Tβ1–14 were 0.19 and 0.58 ng/mL, respectively, and showed a good linearity (r2 = 0.9998). As a result, among the six metabolites above, Ac‐Tβ1–14, as a common metabolite, was found in LAP, HKM, huvec cells exposed to Tβ4, and the urine of rats intraperitoneally treated with 20‐mg/kg Tβ4. And the metabolite Ac‐Tβ1–14 was quantitatively determined by 48 h in rats, with the highest concentration occurring between 0 and 6 h. Ac‐Tβ1–14 was not detected in non‐treated control groups, including human blank urine. These results suggest that Ac‐Tβ1–14 in urine is a potential biomarker for screening the parent Tβ4 in doping tests.
- Open Access
- 2 February 2023
- Published by Wiley in Drug Testing and Analysis
- Vol. 15 (11-12) , 1329-1343
Metabolites identification of anabolic steroid bolasterone in vitro and in rats by high resolution liquid chromatography mass spectrometry
Bolasterone (7α,17α–dimethyltestosterone) and anabolic androgenic steroids are included in the World Anti‐Doping Agency's Prohibited list of substances. This study aimed to evaluate the metabolism of bolasterone through in vitro experiments using rat liver microsomes and in vivo experiments using rat urine after oral administration. Urine samples were collected over a 168‐h period. Bolasterone and its metabolites were detected by liquid chromatography coupled with a Q‐Exactive Obitrap mass spectrometry (LC‐HRMS). Ultimately 16 hydroxylated metabolites (M1–M16), one metabolite from the reduction of the 3‐keto function and 4‐ene (M17), and one glucuronic acid conjugated metabolite (M18) were detected. Metabolites M17 and M18 were confirmed by comparison with available reference or authentic standards. Metabolic modifications in the structure of the parent bolasterone result in different fragmentation patterns. Based on the sensitivity of the HRMS data, characteristic ions such as m/z 121.064 (C8H9O) generated from ring A of the mono‐hydroxylated metabolites and 121.101 (C9H13) generated from ring D of the di‐hydroxylated metabolites were observed that helped differentiate between the obtained metabolites. The structures of fragment ions were tentatively proposed based on their fragmentation pathways, where the significant ions were correlated to the possible structural fragments. In conclusion, new metabolites of bolasterone were detected and characterized by the use of the full‐scan and dd‐MS/MS using LC‐HRMS, and this data can be useful for providing metabolite information for the interpretation of mass spectra of anabolic bolasterone analogues for doping screening tests.
- 2 February 2023
- Published by Wiley in Drug Testing and Analysis
- Vol. 15 (11-12) , 1329-1343
Open AccessMetabolites identification of anabolic steroid bolasterone in vitro and in rats by high resolution liquid chromatography mass spectrometry
Bolasterone (7α,17α–dimethyltestosterone) and anabolic androgenic steroids are included in the World Anti‐Doping Agency's Prohibited list of substances. This study aimed to evaluate the metabolism of bolasterone through in vitro experiments using rat liver microsomes and in vivo experiments using rat urine after oral administration. Urine samples were collected over a 168‐h period. Bolasterone and its metabolites were detected by liquid chromatography coupled with a Q‐Exactive Obitrap mass spectrometry (LC‐HRMS). Ultimately 16 hydroxylated metabolites (M1–M16), one metabolite from the reduction of the 3‐keto function and 4‐ene (M17), and one glucuronic acid conjugated metabolite (M18) were detected. Metabolites M17 and M18 were confirmed by comparison with available reference or authentic standards. Metabolic modifications in the structure of the parent bolasterone result in different fragmentation patterns. Based on the sensitivity of the HRMS data, characteristic ions such as m/z 121.064 (C8H9O) generated from ring A of the mono‐hydroxylated metabolites and 121.101 (C9H13) generated from ring D of the di‐hydroxylated metabolites were observed that helped differentiate between the obtained metabolites. The structures of fragment ions were tentatively proposed based on their fragmentation pathways, where the significant ions were correlated to the possible structural fragments. In conclusion, new metabolites of bolasterone were detected and characterized by the use of the full‐scan and dd‐MS/MS using LC‐HRMS, and this data can be useful for providing metabolite information for the interpretation of mass spectra of anabolic bolasterone analogues for doping screening tests.
- 8 July 2022
- Published by Springer Nature in Journal of Pharmaceutical Investigation
- Vol. 52 (5) , 611-621
An approach for identifying in silico peptides against authentic metabolites: in vitro characterization of thymosin β4 metabolites
- 8 July 2022
- Published by Springer Nature in Journal of Pharmaceutical Investigation
- Vol. 52 (5) , 611-621
An approach for identifying in silico peptides against authentic metabolites: in vitro characterization of thymosin β4 metabolites
- 14 December 2019
- Published by Springer Nature in Journal of Pharmaceutical Investigation
- Vol. 50 (5) , 481-491
Severity of the autoimmune encephalomyelitis symptoms in mouse model by inhibition of LAT-1 transporters
- 14 December 2019
- Published by Springer Nature in Journal of Pharmaceutical Investigation
- Vol. 50 (5) , 481-491
Severity of the autoimmune encephalomyelitis symptoms in mouse model by inhibition of LAT-1 transporters
- 1 September 2019
- Published by Elsevier in Neuroscience
- Vol. 416, 74-87
Identification of Altered Metabolic Pathways during Disease Progression in EAE Mice via Metabolomics and Lipidomics
- 1 September 2019
- Published by Elsevier in Neuroscience
- Vol. 416, 74-87
Identification of Altered Metabolic Pathways during Disease Progression in EAE Mice via Metabolomics and Lipidomics
- 6 February 2019
- Published by Wiley in Proteomics
- Vol. 19 (5) , e1800355
Quantitative Proteome Analysis of Brain Subregions and Spinal Cord from Experimental Autoimmune Encephalomyelitis Mice by TMT‐Based Mass Spectrometry
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS); its cause is unknown. To understand the pathogenesis of MS, researchers often use the experimental autoimmune encephalomyelitis (EAE) mouse model. Here, the aim is to build a proteome map of the biological changes that occur during MS at the major onset sites—the brain and the spinal cord. Quantitative proteome profiling is performed in five specific brain regions and the spinal cord of EAE and healthy mice with high‐resolution mass spectrometry based on tandem mass tags. On average, 7400 proteins per region are quantified, with the most differentially expressed proteins in the spinal cord (1691), hippocampus (104), frontal cortex (83), cerebellum (63), brainstem (50), and caudate nucleus (41). Moreover, region‐specific and commonly expressed proteins in each region are identified and bioinformatics analysis is performed. Pathway analysis reveals that protein clusters resemble their functions in disease pathogenesis (i.e., by inducing inflammatory responses, immune activation, and cell–cell adhesion). In conclusion, the study provides an understanding of the pathogenesis of MS in the EAE animal model. It is expected that the comprehensive proteome map of the brain and spinal cord can be used to identify biomarkers for the pathogenesis of MS.
- 6 February 2019
- Published by Wiley in Proteomics
- Vol. 19 (5) , e1800355
Quantitative Proteome Analysis of Brain Subregions and Spinal Cord from Experimental Autoimmune Encephalomyelitis Mice by TMT‐Based Mass Spectrometry
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS); its cause is unknown. To understand the pathogenesis of MS, researchers often use the experimental autoimmune encephalomyelitis (EAE) mouse model. Here, the aim is to build a proteome map of the biological changes that occur during MS at the major onset sites—the brain and the spinal cord. Quantitative proteome profiling is performed in five specific brain regions and the spinal cord of EAE and healthy mice with high‐resolution mass spectrometry based on tandem mass tags. On average, 7400 proteins per region are quantified, with the most differentially expressed proteins in the spinal cord (1691), hippocampus (104), frontal cortex (83), cerebellum (63), brainstem (50), and caudate nucleus (41). Moreover, region‐specific and commonly expressed proteins in each region are identified and bioinformatics analysis is performed. Pathway analysis reveals that protein clusters resemble their functions in disease pathogenesis (i.e., by inducing inflammatory responses, immune activation, and cell–cell adhesion). In conclusion, the study provides an understanding of the pathogenesis of MS in the EAE animal model. It is expected that the comprehensive proteome map of the brain and spinal cord can be used to identify biomarkers for the pathogenesis of MS.